Biomedicine

Polyurethane nanoparticles (PU NPs,a novel material)-basedhemostatic agents

Principal Investigator: Abel, Po-Hao Huang M.D. 
Abstract

To satisfy this unmet medical need and grab the business opportunity, our team combined experts from medicine, technology, research and business, and designed a novel hemostatic product based on "nanomedical" materials, namely, polyurethane nanoparticles (PU NPs). PU NP has been proved to exhibit anti-inflammatory effect in vitro, and product prototype has been demonstrated to induce almost no foreign body reactions and probably exhibit neuroprotective effects in vivo. Additionally, PU NP can enclose drugs, therefore, our product holds the potential to develop second and event third generation with multiple functions. Our team needs suggestions and financial support of Industrial Value Creation Program for Academiain order to establish pilot production and complete the tests of biocompatibility and functional performance under the guidance of Food and Drug Administration, which is the basis of clinical application and lucrative growth of our product.

1learn more
Team Introduction

Team leader, Abel Po-Hao Huang was Clinical Assistant Professor, Department of Surgery, College of Medicine, National Taiwan University and Attending Physician, Division of Neurosurgery, Department of Surgery, National Taiwan University Hospital. He participated Fellowship, Stanford Taiwan Biodesign program during July 2014 - July 2015.

Co-PI, Shan-hui Hsu, received her Professor, Ph.D. in Case Western Reserve and was Director of Institute of Polymer Science and Engineering in NTU. She is an active researcher in the fields of biomaterials, polyurethane, tissue engineering, and nanomaterials. She has published lots of journal papers and generated more than 20 patents. Her paper has been cited thousands times. We have been a common vision: recreate the way of healthcare and help people healthier life.

Goals and Plan

Our goal is applying novel scientific research to human health solutions. With the breakthrough of surgical techniques and having kept up with the times, the use of hemostatic materials for surgery requires a hemostatic product with better performance and wider application. We plan to establish pilot production and complete the tests of biocompatibility and functional performance under the guidance of Food and Drug Administration, which is the basis of clinical application and lucrative growth of our product. In the future, we will develop second and third generation products.

Entry Barrier

PU NP has been proved to exhibit anti-inflammatory effect in vitro, and product prototype has been demonstrated to induce almost no foreign body reactions and probably exhibit neuroprotective effects in vivo. Additionally, PU NP can enclose drugs, therefore, our product holds the potential to develop second and event third generation with multiple functions. Our team needs suggestions and financial support of Industrial Value Creation Program for Academiain order to establish pilot production and complete the tests of biocompatibility and functional performance under the guidance of Food and Drug Administration, which is the basis of clinical application and lucrative growth of our product.

Market Scope

Hemostatic agents are medical devices used to cease bleeding and hemorrhage caused by injuries and surgical procedures. The global market size of hemostatic agents was valued at USD 3.8 billion in 2016. The market is expected to witness lucrative growth over the next seven years, owing to an increase in demand supported by rising surgery volumes.

Video Introduction